Equities research analysts predict that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will post ($0.64) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Dicerna Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.28). Dicerna Pharmaceuticals posted earnings per share of ($0.68) in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.9%. The business is expected to issue its next quarterly earnings report on Thursday, March 29th.
Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.22). The company had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The business’s quarterly revenue was up 192.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.68) earnings per share.
Dicerna Pharmaceuticals (NASDAQ DRNA) traded down $0.14 on Friday, hitting $8.83. The stock had a trading volume of 162,162 shares, compared to its average volume of 316,233. The firm has a market cap of $455.99, a price-to-earnings ratio of -2.57 and a beta of 2.85. Dicerna Pharmaceuticals has a 12 month low of $2.42 and a 12 month high of $10.24.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $1,995,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 29.41% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Deschutes Portfolio Strategy LLC bought a new position in Dicerna Pharmaceuticals in the third quarter valued at about $575,000. Palo Alto Investors LLC raised its position in Dicerna Pharmaceuticals by 4.0% in the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock valued at $1,588,000 after purchasing an additional 19,394 shares during the last quarter. Birchview Capital LP raised its position in Dicerna Pharmaceuticals by 125.0% in the third quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock valued at $259,000 after purchasing an additional 25,000 shares during the last quarter. EcoR1 Capital LLC raised its position in Dicerna Pharmaceuticals by 101.0% in the second quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock valued at $2,435,000 after purchasing an additional 385,992 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 14,517 shares during the last quarter. Hedge funds and other institutional investors own 21.93% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.